リンパ球減少症治療法の世界市場予測・分析:後天性リンパ球減少症、遺伝性リンパ球減少症

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Acquired lymphopenia – Market size and forecast 2018-2023
• Inherited lymphopenia – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Increasing research in regenerative medicines
• Strategic alliances
• Presence of patient assistance programs
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Bristol-Myers Squibb Co.
• CSL Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Grifols SA
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Novartis AG
• Sanofi
PART 13: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors


Exhibit 01: Years in consideration
Exhibit 02:
Exhibit 03: Global pharmaceuticals market
Exhibit 04: Segments of global pharmaceuticals market
Exhibit 05: Market characteristics
Exhibit 06: Market characteristics analysis
Exhibit 07: Market segments
Exhibit 08: Market definition – Inclusions and exclusions checklist
Exhibit 09: Market size 2018
Exhibit 10: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition – Five forces 2018
Exhibit 20: Product – Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Acquired lymphopenia – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Acquired lymphopenia – Year-over-year growth 2019-2023 (%)
Exhibit 24: Inherited lymphopenia – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Inherited lymphopenia – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Customer landscape analysis
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Decision framework
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendor landscape analysis
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. – Vendor overview
Exhibit 54: AbbVie Inc. – Business segments
Exhibit 55: AbbVie Inc. – Organizational developments
Exhibit 56: AbbVie Inc. – Geographic focus
Exhibit 57: AbbVie Inc. – Key offerings
Exhibit 58: AbbVie Inc. – Key customers
Exhibit 59: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 60: Bristol-Myers Squibb Co. – Business segments
Exhibit 61: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 62: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 63: Bristol-Myers Squibb Co. – Key offerings
Exhibit 64: Bristol-Myers Squibb Co. – Key customers
Exhibit 65: CSL Ltd. – Vendor overview
Exhibit 66: CSL Ltd. – Business segments
Exhibit 67: CSL Ltd. – Organizational developments
Exhibit 68: CSL Ltd. – Geographic focus
Exhibit 69: CSL Ltd. – Segment focus
Exhibit 70: CSL Ltd. – Key offerings
Exhibit 71: CSL Ltd. – Key customers
Exhibit 72: Gilead Sciences Inc. – Vendor overview
Exhibit 73: Gilead Sciences Inc. – Business segments
Exhibit 74: Gilead Sciences Inc. – Organizational developments
Exhibit 75: Gilead Sciences Inc. – Geographic focus
Exhibit 76: Gilead Sciences Inc. – Key offerings
Exhibit 77: Gilead Sciences Inc. – Key customers
Exhibit 78: GlaxoSmithKline Plc – Vendor overview
Exhibit 79: GlaxoSmithKline Plc – Business segments
Exhibit 80: GlaxoSmithKline Plc – Organizational developments
Exhibit 81: GlaxoSmithKline Plc – Geographic focus
Exhibit 82: GlaxoSmithKline Plc – Segment focus
Exhibit 83: GlaxoSmithKline Plc – Key offerings
Exhibit 84: GlaxoSmithKline Plc – Key customers
Exhibit 85: Grifols SA – Vendor overview7
Exhibit 86: Grifols SA – Business segments7
Exhibit 87: Grifols SA – Organizational developments
Exhibit 88: Grifols SA – Geographic focus
Exhibit 89: Grifols SA – Segment focus
Exhibit 90: Grifols SA – Key offerings
Exhibit 91: Grifols SA – Key customers
Exhibit 92: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 93: Johnson & Johnson Services Inc. – Business segments
Exhibit 94: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 95: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 96: Johnson & Johnson Services Inc. – Segment focus
Exhibit 97: Johnson & Johnson Services Inc. – Key offerings
Exhibit 98: Johnson & Johnson Services Inc. – Key customers
Exhibit 99: Merck & Co. Inc. – Vendor overview
Exhibit 100: Merck & Co. Inc. – Business segments
Exhibit 101: Merck & Co. Inc. – Organizational developments
Exhibit 102: Merck & Co. Inc. – Geographic focus
Exhibit 103: Merck & Co. Inc. – Segment focus
Exhibit 104: Merck & Co. Inc. – Key offerings
Exhibit 105: Merck & Co. Inc. – Key customers
Exhibit 106: Novartis AG – Vendor overview
Exhibit 107: Novartis AG – Business segments
Exhibit 108: Novartis AG – Organizational developments
Exhibit 109: Novartis AG – Geographic focus
Exhibit 110: Novartis AG – Segment focus
Exhibit 111: Novartis AG – Key offerings
Exhibit 112: Novartis AG – Key customers
Exhibit 113: Sanofi – Vendor overview
Exhibit 114: Sanofi – Business segments
Exhibit 115: Sanofi – Organizational developments
Exhibit 116: Sanofi – Geographic focus
Exhibit 117: Sanofi – Segment focus
Exhibit 118: Sanofi – Key offerings
Exhibit 119: Sanofi – Key customers
Exhibit 120: Validation techniques employed for market sizing
Exhibit 121: List of abbreviations
Exhibit 122: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様